- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03846414
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
18. februar 2019 oppdatert av: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Real World Study of PEGylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Prevention of Chemotherapy-induced Neutropenia
The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000
patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.The primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade IV neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.
Studieoversikt
Status
Ukjent
Intervensjon / Behandling
Studietype
Observasjonsmessig
Registrering (Forventet)
1500
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.
Beskrivelse
Inclusion Criteria:
- Patients' age≥18 years old, male or female
- Diagnosis of non-myeloid malignant solid tumors
- Patients are planned to perform chemotherapy and preventive use the PEG-rhG-CSF or preventive or therapeutic use of rhG-CSF after chemotherapy
- Patients' mental status are well, could understand the study and willing to participate the study, sign the informed consent form
- The investigator believes that patients can benefit from this study
Exclusion Criteria:
- Patients who have been confirmed to be allergic to Jinyouli® or rhG-CSF or its excipients
- Pregnant or lactating women and women who plan to be pregnant during clinical observation
- Other patients that the doctor believe not suitable for inclusion
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
PEG-rhG-CSF group
This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle.
The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
|
PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Andre navn:
|
|
rhG-CSF group
This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cost-Effectiveness
Tidsramme: through the chemotherapy cycles of PEG-rhG-CSF or rhG-CSF treatment,an average of 3 month
|
Based on the results of the incidence of febrile neutropenia(FN) and the cost perFN in each group, the incremental cost-effectiveness ratio were estimated using the following formula: (CostA-CostB)/(OutcomeA-OutcomeB)
|
through the chemotherapy cycles of PEG-rhG-CSF or rhG-CSF treatment,an average of 3 month
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of febrile neutropenia
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
Febrile neutropenia (FN) is defined as oral temperature >38.3 ℃(under arm temperature >38.1 ℃) or continuous measurement of oral temperature >38℃(under arm temperature >37.8℃) in 2h, and absolute neutrophil count(ANC) <0.5×10^9/L, or expected to be <0.5×10^9/L
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The incidence of grade IV neutropenia
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
Grade IV neutropenia is defined as the absolute neutrophil count(ANC)<0.5×10^9/L
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The duration of grade IV neutropenia in every chemotherapy cycle
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
Defined as days when the ANC<2.0×10^9/L
occurs to the time when the ANC≥2.0×10^9/L,
take the median
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The incidence of the chemotherapy delay
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
Chemotherapy delay is defined as the delay in starting the next planned chemotherapy for more than 3 days.
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The duration of the chemotherapy delay in every chemotherapy cycle
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
The duration of the chemotherapy delay in every chemotherapy cycle
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
The incidence of the dose reduction
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
The incidence of the reduction of planned dose of chemotherapy
|
From date of randomization until the date of the study completion,an average of 3 month
|
|
Relative chemotherapy dose intensity in every chemotherapy cycle
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
Relative chemotherapy dose intensity is defined as the actual chemotherapy dose the patient used divided by the planned chemotherapy dose,or the actual chemotherapy time divided by the planned chemotherapy time
|
From date of randomization until the date of the study completion,an average of 3 month
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
|
All adverse events will be recorded from the time of patients signing the informed consent form up to 30 days after the last Intervention drug is applied.
the adverse event that associated with the study drug will be specially recorded.
|
From date of randomization until the date of the study completion,an average of 3 month
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
13. februar 2019
Primær fullføring (Forventet)
1. april 2020
Studiet fullført (Forventet)
1. oktober 2020
Datoer for studieregistrering
Først innsendt
14. februar 2019
Først innsendt som oppfylte QC-kriteriene
18. februar 2019
Først lagt ut (Faktiske)
19. februar 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. februar 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
18. februar 2019
Sist bekreftet
1. februar 2019
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CSPC-JYL-RWS-07
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
IPD will only be shared by the investigators in this study
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .